FDA Approves NEBIVOLOL — Solco Healthcare US, LLC

# FDA Approves Generic Nebivolol; Solco Healthcare Entry Expected to Intensify Competition in Beta-Blocker Market Solco Healthcare US, LLC received FDA approval for generic nebivolol (ANDA212682) on April 7, 2022, marking another entrant into the competitive cardiovascular drug segment and likely to apply pricing pressure on the branded formulation. The oral generic is expected to capture market share from existing nebivolol products, benefiting patients through lower-cost treatment options for hypertension and heart failure.